您当前的位置:首页 > 关于云克 > 发展历程

发展历程

/FootPrint

十年征程

THE TRACE OF 10 YEARS
    1997年,历经八年科研,中国核动力研究设计院同位素应用研究所成功研制我国自六十年代起至今两个国产核素药物之一——锝[99Tc]亚甲基二膦酸盐注射液。该产品获得“国家发明专利证书”以及“国家重点新产品证书”。从此,我们从以前单纯的放免试剂和体内显像试剂供应商逐渐丰富发展为以核素药品供应为主的核技术专业服务供应商。
   In 1997, the Chengdu Isotope Application Institution(CIAI) of the Nuclear Power Institute of China successfully invented the technetium[99Tc] methylenediphosphonate injection (YUNKE) which was the 2nd radiopharmaceuticals developed in our country since 1960s. From then on, the CIAI and latter the CYPC gradually developed to be a special enterprise providing advanced products and services in the field of diagnostic nuclear medicine and therapeutic nuclear medicine.
    2000年,正式获得锝[99Tc]亚甲基二膦酸盐注射液生产批文。同年,获得另外两个产品专利。
   In 2000, YUNKE was approved for formal manufacture by the SFDA. Besides, two new drugs were patented.
    2001年10月,云克药业有限责任公司成立,同年获得“成都市高新技术企业认定证书”。
   In Oct., 2001, CYPC was established and was certificated as ‘Chengdu High-tech Enterprise’.
    2002年,云克药业成为行业内首家获得GMP认证证书的核素药物生产企业。
   In 2002, CYPC was approved for the Good Manufacturing Practices (GMP) by the SFDA. And it was the 1st enterprise in the radiopharmaceuticals field. 
    2002年,举办“云克专题国际研讨会”,会上中外专家就云克药物的研究及应用进行了热烈的专题讨论,为未来几年内云克药物的科研和临床应用提出了大量宝贵意见和建议。
   In 2002, a special seminar on YUNKE was hold in Chengdu. On the seminar, experts discussed the mechanisms of YUNKE on treatment of RA, AS etc. and exchanged experiences on application of YUNKE.
    2002年,国际原子能机构和国际卫生组织的专家对我公司项目进行了考察。
   In 2002, experts from the International Atomic Energy Agency(IAEA) and the World Health Organization(WHO) visited the CYPC.
    2003年,国务院学位委员会授权我公司设立“核技术及应用博士点”。
   In 2003, the CYPC was designated to confer the doctoral degrees of nuclear technology and application program by the Evaluation Committee of Academic Degrees of the State Council.
    2006年, I-125密封籽源项目研发成功,预计将于2009年正式推向市场,并进行相关配套产品研发。
   In 2006, 125I sealed seeds source was developed successfully and was expected to enter market in 2009. Now, radioactive stent using 125I sealed seeds source is under development.
    2006年,与成都市红十字会以及成都市青羊区中医医院合作,开展“救治类风湿关节炎特困患者爱心活动”。
   In 2006, cooperated with the Red Cross Society of China, Chengdu City Branch and the Qingyang Section Herbalist Hospital, the CYPC sponsored a patient assistance social activity by fee-free drug(YUNKE) providing and treatment for the especially poor patients of RA.
    2006年,我公司被授予“四川省建设创新型企业”称号。
   In Oct., 2001, CYPC was established and was certificated as ‘Constructive innovational Enterprise of Sichuan Province’.
 
 
企业邮局 | 联系我们 | 版权声明 | 法律声明 | 设为首页 | 加入收藏 | Copyright©成都云克药业有限责任公司 版权所有 | 蜀ICP备11019119号 互联网药品信息服务资格证书编号:(川)-非经营性-2016-0061 本网站未发布麻醉药品、精神药品、医疗用毒性药品、戒毒药品和医疗机构制剂的产品信息 声明:本站部分图片信息来自网络,如涉及到版权,请及时联系我们

川公网安备 51019002000571号